Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients

Renard, Laurette; Clement, P. M.; Hammouch, Fatima; Boterberg, T.; Verschaeve, V.; Whenham, N.; Mitine, C.; Devriendt, D.; Baurain, Jean-François

doi:10.1093/neuonc/noq085

Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients

Renard, Laurette

;

Clement, P. M.

;

Hammouch, Fatima

;

Boterberg, T.

;

Baurain, Jean-François

;et.al.

(2010) 9th Meeting of The European Association of NeuroOncology — Location: Maastricht(Netherlands) (16.September.2010)

Files

58558.pdf

Open Access
Adobe PDF
60.95 KB

Download

Details

Authors

Renard, LauretteUCLouvain
Author
Clement, P. M.
Author
Hammouch, FatimaUCLouvain
Author
Boterberg, T.
Author
Baurain, Jean-FrançoisUCLouvain
Author

Affiliations

UCLouvainSSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCLouvain(SLuc) Unité d'oncologie médicale
UCLouvainSSS/IREC/SLUC - Pôle St.-Luc
UCLouvain(SLuc) Service de radiothérapie oncologique

Citations

APA
Chicago
FWB

Renard, L., Clement, P. M., Hammouch, F., Boterberg, T., Verschaeve, V., Whenham, N., Mitine, C., Devriendt, D., & Baurain, J.-F. (2010). Safety analysis of randomized Belgian phase II trial of extended use of adjuvant temozolomide in newly diagnosed glioblastoma patients. Neuro-Oncology, 12(Suppl. 3), 46-47. https://doi.org/10.1093/neuonc/noq085 (Original work published 2010)